LCTX · Lineage Cell Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| BROADWOOD PARTNERS, L.P. 10% Owner | ▲ Buy | Open Market | 49,560,992 Shares held | 1/27/2025 | View profile |
| Michael H. Mulroy Director | ▲ Buy | Open Market | 298,555 Shares held | 11/22/2024 | View profile |
| Brian M. Culley President and CEO | ▲ Buy | Open Market | 255,516 Shares held | 3/12/2026 | View profile |
| BAILEY DON M Director | ▲ Buy | Open Market | 158,801 Shares held | 2/8/2024 | View profile |
| Amin Dipti Director | ▲ Buy | Open Market | 35,000 Shares held | 3/28/2022 | View profile |
| George A. Samuel III General Counsel/Secretary | ▼ Sell | Tax Withholding | 31,063 Shares held | 2/11/2026 | View profile |
| Jill Ann Howe Chief Financial Officer | ▲ Buy | Open Market | 25,500 Shares held | 11/26/2024 | View profile |
| Anula Jayasuriya Director | ▲ Buy | Open Market | 10,000 Shares held | 12/29/2023 | View profile |
| Hogge Gary S. SVP,Clinical & Medical Affairs | ▼ Sell | Tax Withholding | 7,710 Shares held | 2/11/2023 | View profile |
Transaction History
| Brian M. Culley | ▲ Buy | Open Market | 15,000 | $24K | 3/12/2026 |
| Brian M. Culley | ▼ Sell | Tax Withholding | 12,869 | $23K | 2/11/2026 |
| George A. Samuel III | ▼ Sell | Tax Withholding | 2,502 | $5K | 2/11/2026 |
| George A. Samuel III | ▲ Buy | Option Exercise | 6,075 | — | 2/11/2026 |
| Brian M. Culley | ▲ Buy | Option Exercise | 31,250 | — | 2/11/2026 |
| George A. Samuel III | ▲ Buy | Grant | 1,735 | — | 12/19/2025 |
| Brian M. Culley | ▲ Buy | Grant | 8,925 | — | 12/19/2025 |
| Brian M. Culley | ▼ Sell | Tax Withholding | 334 | $561 | 12/19/2025 |
| George A. Samuel III | ▼ Sell | Tax Withholding | 65 | $109 | 12/19/2025 |
| George A. Samuel III | ▲ Buy | Option Exercise | 6,076 | — | 2/11/2025 |
| George A. Samuel III | ▼ Sell | Tax Withholding | 2,440 | $2K | 2/11/2025 |
| Brian M. Culley | ▲ Buy | Option Exercise | 31,249 | — | 2/11/2025 |
| Brian M. Culley | ▼ Sell | Tax Withholding | 12,547 | $8K | 2/11/2025 |
| BROADWOOD PARTNERS, L.P. | ▲ Buy | Open Market | 0 | $0 | 1/27/2025 |
| BROADWOOD PARTNERS, L.P. | ▲ Buy | Open Market | 7,894,737 | $6.0M | 1/27/2025 |
| Jill Ann Howe | ▲ Buy | Open Market | 15,000 | $9K | 11/26/2024 |
| George A. Samuel III | ▲ Buy | Open Market | 15,000 | $9K | 11/26/2024 |
| Michael H. Mulroy | ▲ Buy | Open Market | 40,000 | $23K | 11/22/2024 |
| Brian M. Culley | ▲ Buy | Open Market | 40,000 | $24K | 11/21/2024 |
| Jill Ann Howe | ▲ Buy | Open Market | 10,500 | $9K | 8/16/2024 |
| Brian M. Culley | ▲ Buy | Open Market | 10,000 | $11K | 5/24/2024 |
| George A. Samuel III | ▼ Sell | Tax Withholding | 2,490 | $3K | 2/11/2024 |
| Brian M. Culley | ▼ Sell | Tax Withholding | 12,806 | $14K | 2/11/2024 |
| Brian M. Culley | ▲ Buy | Option Exercise | 31,249 | — | 2/11/2024 |
| George A. Samuel III | ▲ Buy | Option Exercise | 6,076 | — | 2/11/2024 |
| BAILEY DON M | ▲ Buy | Open Market | 96,155 | $100K | 2/8/2024 |
| BROADWOOD PARTNERS, L.P. | ▲ Buy | Open Market | 0 | $0 | 2/6/2024 |
| BROADWOOD PARTNERS, L.P. | ▲ Buy | Open Market | 6,730,770 | $7.0M | 2/6/2024 |
| Anula Jayasuriya | ▲ Buy | Open Market | 10,000 | $11K | 12/29/2023 |
| Hogge Gary S. | ▼ Sell | Tax Withholding | 5,310 | $7K | 2/11/2023 |
| Brian M. Culley | ▲ Buy | Option Exercise | 31,249 | — | 2/11/2023 |
| Brian M. Culley | ▼ Sell | Tax Withholding | 12,744 | $17K | 2/11/2023 |
| George A. Samuel III | ▲ Buy | Option Exercise | 6,076 | — | 2/11/2023 |
| Hogge Gary S. | ▲ Buy | Option Exercise | 13,020 | — | 2/11/2023 |
| George A. Samuel III | ▼ Sell | Tax Withholding | 2,478 | $3K | 2/11/2023 |
| Brian M. Culley | ▼ Sell | Tax Withholding | 5,343 | $8K | 6/30/2022 |
| Brian M. Culley | ▲ Buy | Option Exercise | 15,450 | — | 6/30/2022 |
| Brian M. Culley | ▼ Sell | Tax Withholding | 5,343 | $8K | 3/31/2022 |
| Brian M. Culley | ▲ Buy | Option Exercise | 15,450 | — | 3/31/2022 |
| Brian M. Culley | ▲ Buy | Open Market | 6,400 | $10K | 3/31/2022 |
| Amin Dipti | ▲ Buy | Open Market | 35,000 | $57K | 3/28/2022 |
| BROADWOOD PARTNERS, L.P. | ▲ Buy | Open Market | 470,000 | $678K | 3/25/2022 |
| Brian M. Culley | ▲ Buy | Open Market | 5,250 | $7K | 3/25/2022 |
| BROADWOOD PARTNERS, L.P. | ▲ Buy | Open Market | 0 | $0 | 3/25/2022 |
| BROADWOOD PARTNERS, L.P. | ▲ Buy | Open Market | 200,000 | $284K | 3/24/2022 |
| BROADWOOD PARTNERS, L.P. | ▲ Buy | Open Market | 0 | $0 | 3/24/2022 |
| Michael H. Mulroy | ▲ Buy | Open Market | 7,000 | $10K | 3/24/2022 |
| BROADWOOD PARTNERS, L.P. | ▲ Buy | Open Market | 260,106 | $355K | 3/23/2022 |
| BROADWOOD PARTNERS, L.P. | ▲ Buy | Open Market | 0 | $0 | 3/23/2022 |
| Brian M. Culley | ▼ Sell | Tax Withholding | 5,343 | $13K | 12/31/2021 |
| Brian M. Culley | ▲ Buy | Option Exercise | 15,450 | — | 12/31/2021 |
| Hogge Gary S. | ▼ Sell | Open Market | 28,445 | $69K | 12/29/2021 |
| Hogge Gary S. | ▼ Sell | Open Market | 9,250 | $23K | 12/29/2021 |
| Hogge Gary S. | ▲ Buy | Option Exercise | 9,250 | $6K | 12/29/2021 |
| Hogge Gary S. | ▲ Buy | Option Exercise | 236,899 | $500K | 12/28/2021 |
| Hogge Gary S. | ▲ Buy | Option Exercise | 185,000 | $128K | 12/28/2021 |
| Hogge Gary S. | ▲ Buy | Option Exercise | 79,689 | $91K | 12/28/2021 |
| Hogge Gary S. | ▼ Sell | Open Market | 501,588 | $1.2M | 12/28/2021 |
| Brian M. Culley | ▲ Buy | Option Exercise | 15,450 | — | 9/30/2021 |
| Brian M. Culley | ▼ Sell | Tax Withholding | 5,343 | $13K | 9/30/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
LCTX Holds Q2 2026 Earnings Conference Call
Lineage Cell Therapeutics held its Q2 2026 earnings conference call, with a transcript released by Benzinga. Management reviewed the quarter's financial results and gave updates on ongoing clinical programs. The discussion provides investors with current insight into the company's performance and future plans. The call occurs while the stock is near its recent support level.
LCTX Holds Q2 2026 Earnings Conference Call. Lineage Cell Therapeutics held its Q2 2026 earnings conference call, with a transcript released by Benzinga. Management reviewed the quarter's financial results and gave updates on ongoing clinical programs. The discussion provides investors with current insight into the company's performance and future plans. The call occurs while the stock is near its recent support level.